Rehak, Matus
Busch, Catharina
Unterlauft, Jan-Darius
Jochmann, Claudia
Wiedemann, Peter
Funding for this research was provided by:
Alimera Sciences
Article History
Received: 4 September 2019
Accepted: 18 October 2019
First Online: 20 November 2019
Conflict of interest
: Matus Rehak is consultant for Allergan, Alimera, Bayer and Novartis; received speaker honoraria from Allergan, Alimera, Bayer, Novartis and Zeiss; and research grant from Novartis (DRKS00000711). Catharina Busch is consultant for Allergan and received speaker honoraria from Allergan and Novartis. Other co-authors have no conflict of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments.
: None.